Disclosure of Editors’ Financial Relationships

The American Journal of Psychiatry requires its editors to disclose any financial relationships with commercial interests, including consulting with pharmaceutical companies or receiving honoraria from them. These relationships were as follows:

Ned H. Kalin, M.D. (Editor-in-Chief): Dr. Kalin reports serving as a consultant to the Board of Scientific Advisors, Pritzker Neuropsychiatric Disorders Consortium; Skyland Trail National Advisory Board, CME Outfitters, LLC and the Institute for Early Adversity Research External Scientific Advisory Board at the University of Texas-Austin; and having stock in Seattle Genetics, Inc.

Elisabeth Binder, M.D., Ph.D. (Deputy Editor): Dr. Binder reports receiving an honorarium from Pfizer.

Kathleen T. Brady, M.D., Ph.D. (Deputy Editor): Dr. Brady reports serving as a consultant to Embera Pharma.

David A. Lewis, M.D. (Deputy Editor): Dr. Lewis reports currently receiving investigator-initiated research support from Pfizer and Merck.

Daniel S. Pine, M.D. (Deputy Editor): Dr. Pine reports no financial relationships with commercial interests.

Carolyn Rodriguez, M.D., Ph.D. (Deputy Editor): Dr. Rodriguez reports in the past 3 years having served as a consultant to Blackthorn and Epiodyne and receiving grant support from Biohaven Pharmaceuticals

Madhukar Trivedi, M.D. (Deputy Editor): Dr. Trivedi reports serving as a consultant or on advisory boards for Academy Health, Acadia Pharmaceuticals, Akili Interactive, Alkermes, Allergan Pharmaceuticals, Axsome Therapeutics, Boehringer Ingelheim, Brintellix Global, Health Research Associates, Janssen Pharmaceutical, Lundbeck Research USA, Medscape, Navitor, One Carbon Therapeutics, Otsuka America Pharmaceutical, Oxford Pharmagenesis Inc., Sage Therapeutics, and Takeda Global Research; receiving royalties/editorial compensation from Healthcare Global Village and Oxford University Press; and receiving grants from Acadia Pharmaceuticals and Janssen Pharmaceutical.